Market closed · Next open: Tuesday 9:30 AM ET
Last update: Sep 14, 2026, 6:10 PM ET

Stock Analysis

Why did AST SpaceMobile (ASTS) stock drop ~15% on July 16, 2026? The $1B convertible, and the capped call behind it

AST SpaceMobile dropped about 14.7% intraday after pricing a $1.0 billion convertible notes offering. The 'dilution' headline skips the capped call that offsets conversion dilution up to a $149.20 cap. The more likely drivers were convertible-arb hedging, the signal of another raise, and a space-sector sell-off.

By BestStocks ResearchPublished (ET)9 min readASTS
AST SpaceMobile direct-to-device satellite over Earth, illustrating the July 2026 selloff after a $1 billion convertible notes offering

Summary

AST SpaceMobile (NASDAQ: ASTS) was trading around $56.55 late Thursday morning, July 16, 2026, down about $9.76, or 14.72%, from Wednesday's $66.31 close, with the session still open [1][2]. The trigger is not in doubt: the company announced the deal Wednesday and, after the close, priced a $1.0 billion offering of convertible senior notes due 2034; the stock gapped down overnight and extended the fall into Thursday [4][6][7].

The one-word explanation making the rounds is "dilution" [15]. That word is doing too much work. The notes convert at $79.57, and they were sold with a capped call whose cap price is $149.20 — a 125% premium over the reference — designed to offset the dilution from conversion up to that level [4]. What is more likely pressing on the tape are drivers the headline understates: mechanical convertible-arbitrage hedging into a stock already 24% short on its float, the signal of a company raising a further $1 billion on top of $2.7 billion of cash, and a broad space-sector sell-off the same day. The exact split between these cannot be proven, but each is documented.

Evidence levelWhat can be said
DocumentedASTS priced $1.0bn of convertible notes after Wednesday's close; the stock opened sharply lower Thursday [4][7].
Mechanically plausibleConvertible buyers may have short-sold ASTS to hedge; a heavily-shorted, launch-exposed name sold off alongside its space peers.
Not measurable from public dataHow much of the ~15% fall came from arb hedging, the financing signal, sector weakness or ordinary selling — the split cannot be quantified.

The sequence — why the move landed today

  • Wed, Jul 15 (morning): ASTS announces its intent to offer $1.0bn of convertible senior notes [6].
  • Wed, Jul 15 (close): shares close at $66.31 — the figure the deal uses as its reference price [2][4].
  • Wed, Jul 15 (after hours): the notes price — 1.625% coupon, $79.57 conversion, a $149.20 capped-call cap [4].
  • Thu, Jul 16: the stock gaps down and trades ~15% lower, near $56.55 by late morning [2].

What changed

MetricValueAs of / source
Intraday price~$56.55Jul 16 2026, ~11:02 a.m. ET — StockAnalysis [2]
Prior close (Jul 15)$66.31Also the offering's reference price [2][4]
Intraday change−$9.76 / −14.72%Vs prior close; session ongoing [2]
Intraday range$56.13 – $61.50 (open $59.20)Jul 16 2026 — StockAnalysis [2]
52-week range$36.08 – $133.86StockAnalysis [2]
Volume by ~11:02 a.m.22.7M shAlready above the full 20-day average of ~18.97M [2][3]
Short interest64.72M sh16.67% of shares out; 24.33% of float [3]
Market cap~$21.7–21.9bnShares out 388.1M (+51.4% y/y) [3]

Two things stand out before the story even begins. First, volume: by late morning ASTS had already traded more shares than it averages in a full session, so participation and turnover were unusually high — though heavy volume measures activity, not conviction, and can equally reflect forced sales, dealer hedging or arbitrage [2][3]. Second, positioning: short interest running near a quarter of the float means a large short base was already in place — which matters for how a convertible lands.

The deal, and the dilution that is not there yet

The terms are specific. ASTS priced $1.0 billion of 1.625% convertible senior notes due February 1, 2034, with a 13-day option for initial purchasers to add $150 million [4]. The base conversion price is $79.57, a 20% premium over Wednesday's $66.31 close (a conversion rate of 12.5672 shares per $1,000 note). Net proceeds are about $983.6 million, and the company spent $96.9 million of that buying capped call transactions whose cap price is $149.20, a 125% premium, structured to offset the dilution from conversion up to that level [4].

Horizontal bar chart showing ASTS at ~$56.55 intraday, the $66.31 reference close, the $79.57 conversion price, and the $149.20 capped-call cap, with the capped call offsetting conversion dilution across the band between them
The capped call is designed to offset conversion dilution across the band from the $79.57 conversion price up to its $149.20 cap. Source: AST SpaceMobile pricing release, July 15, 2026 [4].

That structure matters. At the conversion price the notes represent roughly 12.6 million shares, about 3.2% of the 388 million outstanding, and only if converted in the money — and the capped call is designed to offset that dilution up to the $149.20 cap, subject to how ASTS elects to settle conversions in cash, shares or a combination [3][4]. So the reflexive "they just diluted me 15%" reading does not describe what happened on paper. The dilution the tape fears is an out-of-the-money conversion feature, heavily hedged — not a share issuance at today's price. This is the same instrument that hit Fermi (FRMI) a week earlier [14] — but the market's reaction to a convertible is rarely about the arithmetic of conversion.

Proceeds & dilution bridgeBase offeringWith $150M option
Principal$1.000bn$1.150bn
Gross shares initially underlying12.57M14.45M
— as % of 388.12M outstanding3.24%3.72%
Net proceeds~$983.6M~$1,131.2M
Initial capped-call cost−$96.9M−$96.9M+
Net proceeds after capped call~$886.7Mn/a (extra cost not yet set)

The share figures are the notes' gross initially underlying shares — the maximum before any capped-call offset and only on conversion — not realised dilution. Source: AST SpaceMobile pricing release [4]; share count from StockAnalysis [3].

What is actually pressuring the stock

Three forces, in rough order of immediacy. First, convertible arbitrage. The institutional buyers of a convertible typically hedge it by short-selling the underlying stock to neutralise the equity delta; that hedging flow arrives precisely at issuance and is mechanical, not a view on the company. Landing on a name where short interest is already 24.33% of the float [3], the marginal supply meets an already-crowded, high-beta name — which may help explain a move larger than the raw dilution math alone would justify.

Second, the signal. ASTS held $2.72 billion of cash and restricted cash at June 30 and is raising roughly another billion anyway [5]. Management is candid about why: the proceeds beyond the capped call fund "additional access to orbit" through partnerships and potential acquisitions to vertically integrate and reduce reliance on third-party launch providers [5][8]. That is a rational long-term move for a company whose BlueBird constellation — about 45 satellites — is now targeted for early 2027 [5], and which is in discussions on a Japanese low-Earth-orbit project with Rakuten whose expected total value runs up to about ¥148 billion (roughly $1 billion) — a figure that is the project's scale, not committed financing or ASTS's own proceeds, and one the filing says is not assured [5]. But a fresh raise before the commercial cellular-broadband service is generating material revenue reads, in the short term, as capital intensity and timeline risk, not confidence.

Third, the sector. This was not an ASTS-only day for space. Rocket Lab fell 10.12% and Intuitive Machines (LUNR) 7.34% in the same session on a broad risk-off tied to an oil-price spike [9][10]. The tell is the control case: Globalstar — ASTS's closest direct-to-device competitor — was essentially flat at −0.42%, and EchoStar fell only 2.59% [11][12]. The direct-to-device theme did not sell off; ASTS and the launch-dependent names did.

Bar chart of July 16 2026 intraday moves: ASTS -14.72%, RKLB -10.12%, LUNR -7.34%, SATS -2.59%, GSAT -0.42%
ASTS fell hardest, and its direct D2D peer barely moved — localising the extra damage to ASTS's own deal, not the D2D theme. Source: StockAnalysis intraday quotes, July 16, 2026 [2][9][11][12].

Analyst view

Read the move as three layers stacked, not one. A broad space sell-off took several points off every launch-exposed name; convertible-arb hedging into a heavily-shorted float took several more off ASTS specifically; and a sentiment reaction to "another billion raised before the service scales" did the rest. What the drop is not is a 15% economic dilution today — the notes convert at $79.57 and the capped call is designed to offset that dilution up to a $149.20 cap, both well above the current price. The scale of the reaction is itself the clue: at −$9.76 across 388.1 million shares, the day's move erased roughly $3.8 billion of equity value — nearly four times the $1.0 billion raised [2][3]. That does not prove an overreaction; it shows the market priced in far more than mechanical share-count dilution. The heavy volume shows unusually high participation, but turnover and information are different things: a mechanical hedging flow can move a stock hard without anyone forming a new view of the business.

The genuine question the raise surfaces is timeline, not solvency. With $2.7 billion already on hand plus ~$984 million net incoming, funding is not the risk; execution is — whether ~45 BlueBird satellites actually fly in early 2027, and whether the Rakuten JV and any launch-provider deal firm up. Those are the things the next few quarters answer; a convertible pricing does not.

What this means for value

ASTS is effectively pre-earnings — it books only nascent revenue, and none yet from the commercial SpaceMobile cellular-broadband service — so a P/E frame does not apply; the scenario prices below are the author's own, loosely anchored to analysts' published target distribution and to milestone outcomes, not to an earnings multiple. As of mid-July the consensus rating is Hold with an average target of $79.78 across 10 analysts (range $41.20 to $108) — a snapshot whose inputs include actions from May and June, not all of them post-deal. Piper Sandler initiated at Buy with a $100 target on July 15, the same calendar day as the raise, though there is no timestamp establishing the note followed the after-hours pricing [13]. The probabilities are the author's illustrative estimates, not forecasts, and sum to 100%.

ScenarioPriceProbabilityKey driver
Bull~$12025%BlueBird flies on the early-2027 schedule, the Rakuten JV finalises, the funding overhang clears; toward the Street high of $108 and the $149.20 cap where the convert itself becomes moot [13]
Base~$8045%Execution roughly on plan, dilution overhang lingers; near the $79.78 consensus target and the $79.57 base conversion price [4][13]
Bear~$4530%Launch slips again, cash burn and capital intensity dominate, convert-arb and heavy short interest keep a lid on it; toward the Street low of $41.20 [3][13]
Probability-weighted value ≈ $79.50 — the ~$56.55 intraday price sits about 29% below that blend (equivalently, the blend implies about 41% upside from the price).

Under these illustrative assumptions — the author's own probabilities and outcomes, not the Street's, and note the bull case sits above the Street's $108 high — Thursday's intraday price sits below the blend. Read that as the market discounting execution risk more heavily than this middling scenario mix does. That gap is not a verdict. It is the price of genuine uncertainty about satellites that have not launched and a joint venture that is not signed; whether it is opportunity or warranted skepticism depends entirely on execution the market cannot yet see. Treat the ~$79.50 figure as the midpoint of a wide $45–$120 distribution driven by launch timing and funding perception, not a target.

What to watch

  • Settlement and any greenshoe exercise (around July 20) — whether initial purchasers take the extra $150 million, and how the convertible-arb short flow unwinds once hedges are set [4].
  • BlueBird launch cadence into early 2027 — the ~45-satellite campaign is the single biggest swing factor between the bull and bear cases [5].
  • The Rakuten / J-LEO joint venture and any launch-provider acquisition — the "access to orbit" the raise is explicitly meant to fund; a signed deal would reframe the raise as offense, not defense [5].
  • Short interest and the convert-arb unwind — a quarter of the float is short, but days-to-cover is a moderate ~3.4 (short interest ÷ the 20-day average volume, and a settlement-date snapshot), so this is amplification, not an obvious squeeze setup; watch whether the arb short established at issuance is later covered [3].

Frequently asked questions

Why did AST SpaceMobile (ASTS) stock fall on July 16, 2026?

After Wednesday's close, ASTS priced a $1.0 billion offering of convertible senior notes due 2034, and the stock gapped down, trading about 14.7% lower near $56.55 intraday on Thursday. The likely drivers were less about raw dilution than convertible-arbitrage short-hedging into a heavily-shorted float, the signal of raising a further $1 billion on top of $2.7 billion of cash, and a broad space-sector sell-off the same day — though the exact split between them cannot be proven.

Does the $1 billion convertible actually dilute ASTS shareholders by 15%?

No. The notes carry a conversion price of $79.57 — a 20% premium — representing roughly 12.6 million shares, about 3.2% of shares outstanding, and only if converted in the money. Crucially, ASTS also bought a capped call designed to offset the conversion premium above the notes' principal, up to a cap of $149.20 — reducing the dilution a conversion would otherwise cause — though the outcome depends on how ASTS settles conversions, in cash, shares or a combination.

What is a capped call and why does it matter here?

A capped call is a hedge a company buys alongside a convertible to offset the dilution from conversion, up to a cap price. ASTS spent $96.9 million of the proceeds to set that cap at $149.20, a 125% premium over the $66.31 reference. It is designed to offset dilution between the $79.57 conversion price and the $149.20 cap, subject to settlement method — which is why the reflexive 'they diluted me 15%' reading does not match the deal's structure.

Was the drop specific to ASTS or a whole-sector move?

Both. Space names sold off broadly on July 16 — Rocket Lab fell about 10% and Intuitive Machines about 7% on an oil-price-driven risk-off. But ASTS's closest direct-to-device competitor, Globalstar, was essentially flat (−0.42%), which is consistent with an ASTS-specific component — its capital raise and heavy short positioning — on top of the sector move, rather than a direct-to-device theme selling off.

What are analysts saying about ASTS?

The consensus rating is Hold with an average price target of $79.78 across 10 analysts, in a wide $41.20–$108 range — a snapshot whose inputs include actions from May and June, not all post-deal. Piper Sandler initiated at Buy with a $100 target on July 15, the same calendar day as the offering, though not necessarily after its pricing. Under the author's own illustrative scenarios (bull $120 / base $80 / bear $45), the ~$56.55 intraday price sat about 29% below a ~$79.50 blend. These figures are descriptive, not investment advice.

View all research →
An abstract visualization of a personal AI assistant interface with glowing conversational elements on a smartphone against a deep blue background, representing Meta's Muse AI agent.
TechnologySeptember 9, 2026 · 8 min read

Meta (META) Jumps as Muse, Its First Paid Personal AI Agent, Puts a Price on AI

Meta rose about 6% to roughly $650 on September 9 after launching Muse, a personal AI agent — and, crucially, attaching a price to it: a free tier plus subscriptions at $20 and $100 a month. For a company that has spent enormous sums building AI infrastructure with little consumer revenue to show for it, Muse is a major new consumer-AI monetization line — its first paid personal-agent product — the proof of concept investors had been waiting for. Muse is an autonomous assistant that reads email, books travel, negotiates, and makes purchases through connected payment systems, rolling out in the US on iOS, Android and the web. The launch also rippled across the mega-caps: Alphabet fell ~2.6% as a capable buying-and-booking agent was read as a competitive threat to Google's search (Amazon also slipped ~2.1%, though it had its own news that day). The context is that Meta had lagged — down ~13% over the past year on AI-cost fears — despite an 82% gross margin, ~28% revenue growth and ~$41 billion of free cash flow, at just 19 times forward earnings. Muse does not resolve the spend-versus-return debate, but it reframes it, and the Street stays overwhelmingly bullish, with an average target implying ~16% upside.

A modern pharmaceutical research laboratory with scientists and rows of analytical equipment, representing Amgen's drug-development pipeline and clinical research.
HealthcareSeptember 8, 2026 · 9 min read

Amgen (AMGN) Falls as a Rival's Lp(a) Trial Failure Clouds Its Pipeline

Amgen fell about 8% to roughly $404 on September 8 even as it posted its own good news that morning — its cancer drug IMDELLTRA, with AstraZeneca's Imfinzi, hit its primary survival goal in a Phase III lung-cancer study. The shares dropped anyway, on a rival's failure: Novartis disclosed late last week that pelacarsen — its drug for lowering lipoprotein(a), or Lp(a), a genetic cardiovascular risk factor — failed the primary goal of its large Phase III outcomes trial, not reducing heart attacks, strokes and cardiovascular deaths despite lowering Lp(a). Because Amgen is racing in the same class with its own experimental drug, olpasiran, the read-through was direct: the first dedicated Phase III cardiovascular-outcomes readout of an Lp(a) therapy came up empty, casting doubt on the science behind the category. A separate same-day BMO Capital downgrade — on valuation and pipeline grounds — formed part of the negative backdrop. What cushioned the fall is that Amgen is a cheap, cash-rich defensive franchise — about 18 times forward earnings, a 2.5% dividend, ~$10 billion of free cash flow — so the Lp(a) opportunity was upside, not the foundation. Even so, the stock had run up ~43% over the year, and the Street was already cautious, with a large share of analysts at Hold and an average target below the pre-drop price.

A close-up of a silicon semiconductor wafer with intricate microchip circuitry reflecting rainbow light, representing advanced chip manufacturing and lithography.
TechnologySeptember 8, 2026 · 8 min read

Intel (INTC) Jumps on a High-NA EUV Milestone, Ahead of TSMC in Deployment

Intel rose about 8% to roughly $103 on September 8 after it and lithography partner ASML announced they have processed more than one million wafers using High-NA EUV — the newest, most advanced chipmaking lithography, by industry accounts more than any rival has run. Intel is deploying the technology on select layers of certain 18A products (chips such as Panther Lake), and reports throughput and yields meeting expectations, giving it a multi-year lead in High-NA production experience — TSMC is generally expected to bring High-NA into high-volume production around 2030, and Samsung targets it for DRAM around 2028. The milestone was the headline, though the stock also had a same-day analyst upgrade and reports of possible processor price increases. For a company whose whole case rests on rebuilding a credible foundry business, it was tangible proof the turnaround is producing real capability. The move caps a staggering ~322% one-year run — yet the fundamentals lag: Intel is still GAAP-unprofitable, and the Street stays cautious, with a Hold consensus (roughly two-thirds of covering analysts on the sidelines) and an average target only about 12% above the price. One firm (Northland) upgraded to Buy on the news; most are waiting for the manufacturing lead to become profit.